Annual report pursuant to Section 13 and 15(d)

Document And Entity Information

v3.22.2
Document And Entity Information - shares
12 Months Ended
Mar. 31, 2022
Jun. 21, 2022
Cover [Abstract]    
Entity Registrant Name ACASTI PHARMA INC.  
Entity Incorporation, State or Country Code Z4  
Entity Tax Identification Number 98-1359336  
Entity Central Index Key 0001444192  
Current Fiscal Year End Date --03-31  
Entity File Number 001-35776  
Entity Address, Address Line One 3009 boul. de la Concorde East, Suite 102  
Entity Address, City or Town Laval  
Entity Address, State or Province QC  
Entity Address, Country CA  
Entity Address, Postal Zip Code H7E 2B5  
City Area Code 450  
Local Phone Number 687-2262  
Entity Filer Category Non-accelerated Filer  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Emerging Growth Company false  
Entity Small Business true  
Entity Interactive Data Current Yes  
ICFR Auditor Attestation Flag false  
Entity Common Stock, Shares Outstanding (in shares)   44,439,758
Entity Shell Company false  
Document Type 10-K  
Document Annual Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus FY  
Amendment Flag false  
Title of 12(b) Security Common Shares, no par value per share  
Security Exchange Name NASDAQ  
No Trading Symbol Flag true  
Auditor Firm ID 85  
Auditor Location Montréal, QC, Canada  
Auditor Name KPMG LLP  
Documents Incorporated by Reference

Portions of the registrant’s Definitive Proxy Statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2022 Annual Meeting of Shareholders, to be filed subsequent to the date hereof, are incorporated by reference into Part III of this annual report. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days after the conclusion of the registrant’s fiscal year ended March 31, 2022.